Skip to main
GNFT
GNFT logo

GNFT Stock Forecast & Price Target

GNFT Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Genfit SA has demonstrated a positive outlook, driven by the reported €59 million in sales from its partner Ipsen for the drug Iqirvo in primary biliary cholangitis (PBC), indicating strong market potential and anticipated acceleration in growth. Additionally, Ipsen's presentation of favorable Phase 2 data in progressive familial intrahepatic cholestasis (PSC) suggests the potential for unlocking further milestones, which could enhance revenue prospects. Furthermore, Genfit's diversified pipeline, coupled with strategic partnerships and a proven execution history, reduces the inherent risks associated with biopharmaceutical development and supports a favorable long-term investment perspective.

Bears say

Genfit SA faces significant clinical and regulatory uncertainties regarding its pipeline assets, which poses a risk to the company's future growth and stability. The recent decision to halt development of VS-01 due to serious adverse events highlights potential safety concerns that may hinder the progression of their treatments in critical patient populations. Furthermore, the company's reliance on external financing to support pipeline expansion introduces additional risks, particularly if current capital is insufficient to meet future development needs.

GNFT has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Genfit - ADR and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Genfit - ADR (GNFT) Forecast

Analysts have given GNFT a Strong Buy based on their latest research and market trends.

According to 1 analysts, GNFT has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Genfit - ADR (GNFT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.